225 related articles for article (PubMed ID: 27692554)
1. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G; Guo M; Jin K; Liu Z; Liu C; Cheng H; Lu Y; Long J; Liu L; Xu J; Ni Q; Yu X
Pancreatology; 2016; 16(6):1057-1062. PubMed ID: 27692554
[TBL] [Abstract][Full Text] [Related]
2. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
[TBL] [Abstract][Full Text] [Related]
3. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
4. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
[TBL] [Abstract][Full Text] [Related]
5. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.
Luo G; Liu C; Guo M; Long J; Liu Z; Xiao Z; Jin K; Cheng H; Lu Y; Ni Q; Yu X
Cancer Lett; 2017 Jan; 385():46-50. PubMed ID: 27840089
[TBL] [Abstract][Full Text] [Related]
6. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
Murakami M; Nagai Y; Tenjin A; Tanaka Y
Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
[TBL] [Abstract][Full Text] [Related]
7. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.
Narimatsu H; Iwasaki H; Nakayama F; Ikehara Y; Kudo T; Nishihara S; Sugano K; Okura H; Fujita S; Hirohashi S
Cancer Res; 1998 Feb; 58(3):512-8. PubMed ID: 9458099
[TBL] [Abstract][Full Text] [Related]
8. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
[TBL] [Abstract][Full Text] [Related]
9. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
10. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
11. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
12. Investigation of unexpected serum CA19-9 elevation in Lewis-negative cancer patients.
Hamada E; Taniguchi T; Baba S; Maekawa M
Ann Clin Biochem; 2012 May; 49(Pt 3):266-72. PubMed ID: 22492877
[TBL] [Abstract][Full Text] [Related]
13. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
14. Distribution of
Guo M; Luo G; Lu R; Shi W; Cheng H; Lu Y; Jin K; Yang C; Wang Z; Long J; Xu J; Ni Q; Liu C; Yu X
FEBS Open Bio; 2017 Nov; 7(11):1660-1671. PubMed ID: 29123975
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.
Nagao K; Itoh Y; Fujita K; Fujime M
Int J Urol; 2007 Sep; 14(9):795-9. PubMed ID: 17760744
[TBL] [Abstract][Full Text] [Related]
16. Comment re: "Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping".
Wannhoff A; Weiss KH; Hackert T; Gotthardt DN
Pancreatology; 2017; 17(3):354-355. PubMed ID: 28434838
[No Abstract] [Full Text] [Related]
17. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
18. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
19. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours.
Sefrioui D; Blanchard F; Toure E; Basile P; Beaussire L; Dolfus C; Perdrix A; Paresy M; Antonietti M; Iwanicki-Caron I; Alhameedi R; Lecleire S; Gangloff A; Schwarz L; Clatot F; Tuech JJ; Frébourg T; Jardin F; Sabourin JC; Sarafan-Vasseur N; Michel P; Di Fiore F
Br J Cancer; 2017 Sep; 117(7):1017-1025. PubMed ID: 28772284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]